Results 41 to 50 of about 8,086 (233)
mAbs, 2021 Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin.
Simone Mester +7 more
doaj +1 more source
, 2013 In the past a lot of different biomolecular therapeutics were developed. A common problem using small molecules in therapy is their reduced serum concentration after short time period. The human body clears therapeutic molecules which have a size beneath the kidney clearance threshold in minutes to hours.
Aline Färber-Schwarz
openalex +4 more sources
Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells [PDF]
Immunology, 1997 Maternal IgG is transferred to the suckling mouse and rat through a major histocompatibility complex (MHC) class I‐related Fc receptor (FcRn) on the brush border of the proximal small intestine. We have previously described a site on the epithelial surface of the human fetal intestine with IgG binding characteristics similar to FcRn. We report here the
E J, Israel +6 more
openaire +2 more sources
Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics
Transplantation, 2020 Alloimmune injury to allografts is mediated by pathogenic donor-specific alloantibodies, usually of the IgG isotype. Currently, strategies used to reduce donor-specific alloantibodies are collectively called desensitization. Despite successes, these treatments have limited efficacy and can be associated with adverse events, infectious complications ...
Stanley C, Jordan +2 more
openaire +3 more sources
An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission
Nature Communications, 2023 SARS-CoV-2 is primarily transmitted through droplets and airborne aerosols, and in order to prevent infection and reduce viral spread vaccines should elicit protective immunity in the airways.
Weizhong Li +11 more
doaj +1 more source
Electron tomography of late stages of FcRn-mediated antibody transcytosis in neonatal rat small intestine [PDF]
, 2012 The neonatal Fc receptor (FcRn) transports maternal immunoglobulin (IgG) across epithelia to confer passive immunity to mammalian young. In newborn rodents, FcRn transcytoses IgG from ingested milk across the intestinal epithelium for release into the ...
Bjorkman, Pamela J. +2 more
core +2 more sources
Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn
Brain Research, 2013 Monoclonal antibody (mAb) engineering that optimizes binding to receptors present on brain vascular endothelial cells has enabled them to cross through the blood-brain barrier (BBB) and access the brain parenchyma to treat neurological diseases. However, once in the brain the extent to which receptor-mediated reverse transcytosis clears mAb from the ...
Philip Cooper +7 more
openalex +3 more sources
Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG [PDF]
, 1995 The neonatal Fc receptor (FcRn) transports maternal IgG from ingested milk in the gut to the bloodstream of newborn mammals. An FcRn dimer was observed in crystals of the receptor alone and of an FcRn-Fc complex, but its biological relevance was unknown.
Bjorkman, Pamela J. +2 more
core +1 more source
Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies [PDF]
Journal of Biological Chemistry, 2014 Albumin is the most abundant protein in blood and plays a pivotal role as a multitransporter of a wide range of molecules such as fatty acids, metabolites, hormones, and toxins. In addition, it binds a variety of drugs. Its role as distributor is supported by its extraordinary serum half-life of 3 weeks.
Sand, Kine Marita Knudsen +10 more
openaire +4 more sources
The immune response to malaria in utero. [PDF]
, 2020 Malaria causes tremendous early childhood morbidity and mortality, providing an urgent impetus for the development of a vaccine that is effective in neonates.
Feeney, Margaret E
core +1 more source